Eli Lilly and Co (LLY) : Willis Investment Counsel scooped up 21,000 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 251,700 shares of Eli Lilly and Co which is valued at $20,191,374.Eli Lilly and Co makes up approximately 1.67% of Willis Investment Counsel’s portfolio.
Other Hedge Funds, Including , Columbia Asset Management reduced its stake in LLY by selling 570 shares or 7.77% in the most recent quarter. The Hedge Fund company now holds 6,766 shares of LLY which is valued at $545,069. Eli Lilly and Co makes up approx 0.19% of Columbia Asset Management’s portfolio.Pitcairn Co boosted its stake in LLY in the latest quarter, The investment management firm added 78 additional shares and now holds a total of 4,291 shares of Eli Lilly and Co which is valued at $357,869. Eli Lilly and Co makes up approx 0.05% of Pitcairn Co’s portfolio.
Eli Lilly and Co opened for trading at $79.68 and hit $79.97 on the upside on Tuesday, eventually ending the session at $79.57, with a gain of 0.35% or 0.28 points. The heightened volatility saw the trading volume jump to 34,07,537 shares. Company has a market cap of $87,833 M.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.